You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

9 Items
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (SC) in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (SC) - Retreatment - Indolent Lymphoma
Drugs Used:
bendamustine (PDRP prior authorization),
May 2019
Cancer Type: Gastrointestinal, Esophagus, Gastric / Stomach     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Drugs Used:
trastuzumab (PDRP prior authorization),
Updated
Oct 2019
Cancer Type: Gastrointestinal, Esophagus, Gastric / Stomach     
Intent: Palliative
Drugs Used:
trastuzumab (PDRP prior authorization),
Updated
Oct 2019
Cancer Type: Lung, Mesothelioma     
Intent: Palliative
Drugs Used:
pemetrexed (PDRP prior authorization),
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab - Previously Untreated Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab - Second Line - Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab (SC) - Previously Untreated Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab (SC) - Second Line - Chronic Lymphocytic Leukemia
Mar 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab - Previously Untreated Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab - Second Line - Chronic Lymphocytic Leukemia
ODB Limited Use
    fludarabine - For the first-line treatment of CLL in combination with rituximab (tablets; with or without cyclophosphamide)
ODB Limited Use
    fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)
New Drug Funding Program
    Rituximab (SC) - Previously Untreated Chronic Lymphocytic Leukemia
Drugs Used:
riTUXimab (subcut) (PDRP prior authorization)
Mar 2019
Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab - Previously Untreated Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab - Second Line - Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab (SC) - Previously Untreated Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab (SC) - Second Line - Chronic Lymphocytic Leukemia
Drugs Used:
riTUXimab (subcut) (PDRP prior authorization)
Mar 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Drugs Used:
irinotecan (PDRP prior authorization),
raltitrexed (Unfunded)
Feb 2018
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Adjuvant, Palliative
Drugs Used:
raltitrexed (Unfunded),
oxaliplatin (PDRP prior authorization)
Feb 2018